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Aims Treatment ‘effects’ are often inferred from non-randomized and observational studies. These studies have inherent
biases and limitations, which may make therapeutic inferences based on their results unreliable. We compared the
conflicting findings of these studies to those of prospective randomized controlled trials (RCTs) in relation to




We searched Medline and Embase to identify studies of the association between non-randomized drug therapy and
all-cause mortality in patients with HF until 31 December 2017. The treatments of interest were: angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists
(MRAs), statins, and digoxin. We compared the findings of these observational studies with those of relevant
RCTs. We identified 92 publications, reporting 94 non-randomized studies, describing 158 estimates of the ‘effect’
of the six treatments of interest on all-cause mortality, i.e. some studies examined more than one treatment and/
or HF phenotype. These six treatments had been tested in 25 RCTs. For example, two pivotal RCTs showed that
MRAs reduced mortality in patients with HF with reduced ejection fraction. However, only one of 12 non-
randomized studies found that MRAs were of benefit, with 10 finding a neutral effect, and one a harmful effect.
...................................................................................................................................................................................................
Conclusion This comprehensive comparison of studies of non-randomized data with the findings of RCTs in HF shows that it
is not possible to make reliable therapeutic inferences from observational associations. While trials undoubtedly
leave gaps in evidence and enrol selected participants, they clearly remain the best guide to the treatment of
patients.
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Introduction
Randomized controlled trials (RCTs) are widely acknowledged to be
the gold standard test of whether or not a drug is beneficial.1–4
Although the biases and limitations of non-randomized, observational
studies have been recognized for decades (Figure 1), studies of this type
purporting to describe the effects of treatment continue to be pub-
lished, even in high-impact journals.5–10 Indeed, the ‘comparative
effectiveness’ and ‘big data’ movements have given non-randomized
studies a new respectability in some peoples’ eyes.11–13 Advocates
point to the use of more sophisticated analytical techniques than in the
past and increasingly larger ‘real-world’ datasets.14–17 If the findings of
observational studies could validly determine the effect of treatments,
such information would clearly be of considerable value. On the other
hand, if such analyses are inherently flawed they serve only to cause
confusion, e.g. the association between hormone replacement therapy
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..and decreased risk of coronary heart disease (CHD)18,19 (Figure 2), and
maybe worse, e.g. lead to discontinuation of effective therapy by physi-
cians or patients misled by the findings.20
There is a particularly strong evidence base for pharmacological
treatments in heart failure (HF), making it an appropriate condition in
which to compare treatment effects established in RCTs with those
reported in non-randomized studies. We have, therefore, compared
the conflicting results of non-randomized studies of the ‘effect’ of
pharmacological treatments with those of RCTs using the same
therapies for HF. Although many publications of this type have used
the word ‘effect’, more correctly they have actually described associ-
ations between treatments and outcomes.
Methods
Search strategy and eligibility criteria
We conducted a comprehensive search of the electronic databases
Medline and Embase to identify observational studies examining the asso-
ciation between non-randomized drug therapy and all-cause mortality in
patients with HF. The drugs of interest were those included in all major
HF guidelines: angiotensin-converting enzyme inhibitors (ACEIs), angio-
tensin receptor blockers (ARBs), beta-blockers, mineralocorticoid recep-
tor antagonists (MRAs), statins (3-hydroxy-3-methyl-glutaryl-coenzyme
A reductase inhibitors), and digoxin, where the effect on all-cause mortal-
ity had been tested in at least one large RCT.21,22 The term ‘heart failure’
was searched in title and keywords relating to outcome data and pharma-
cotherapy were searched in title or abstract to retrieve all potentially
relevant articles (see Supplementary material online, Figures S1–S5). The
search, updated until 31 December 2017, was limited to studies of adults,
published in the English language, with more than 100 participants in both
the study drug and control groups, with a minimum follow-up period of
six months. Studies of patients with left ventricular systolic dysfunction
and/or HF after myocardial infarction were not included. We also
excluded studies describing only subgroups of patients with HF, e.g. those
with HF and chronic kidney disease, HF and diabetes etc. Bibliographies
of meta-analyses, guidelines, reviews, and manuscripts identified through
the search strategy were also hand-searched for additional eligible stud-
ies. The review was conducted according to the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.23
Non-randomized studies were considered for inclusion in this review
if the following requirements were met:
(1) Inclusion of patients with HF
(2) Report of the ‘effect’ of the drug of interest on all-cause mortality
(3) Estimate of treatment ‘effect’ provided as a multivariate-adjusted
hazard ratio (HR), risk ratio/relative risk, or odds ratio
Data extraction, synthesis, and risk of bias
Data from the manuscripts identified through the search criteria were
abstracted and tabulated by one reviewer (C.J.R.). The data were inde-
pendently verified by a second reviewer (R.T.C.), with a third reviewer
(J.J.M.) resolving any discrepancies. The articles retrieved were catego-
rized according to HF phenotype, based on ejection fraction (EF), and
drug class for comparison with the relevant randomized trials. For studies
that reported more than one multivariable-adjusted ‘effect’ estimate, the
estimate which had been adjusted for most confounders was used.
A two-tailed P-value of 0.05 was considered significant.
The quality of each study was assessed with the Cochrane
Collaboration Risk of Bias tool for RCTs and the Risk of Bias Assessment
tool for Non-randomized Studies (RoBANS) tool for observational
Figure 1 Confounding in non-randomized studies.
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..studies (see Supplementary material online, Tables S1 and S2).24,25 Studies
judged as having a low risk of bias have been presented separately from
those with a high or unclear risk of bias in the Supplementary material on-
line, Figures S6–S19.
Results
We identified 92 publications reporting 94 non-randomized stud-
ies.26–117 Together, these described 158 estimates of the ‘effect’ of
the six treatments of interest on all-cause mortality. These six treat-
ments had been tested in 25 RCTs.118–147 The results of our analyses
are summarized in Table 1 and described in detail in Tables 2–6. The
forest plots in the Supplementary material online, Figures S6–S19 illus-
trate the treatment effects/association between treatment and out-
comes in the trials and observational studies, respectively, reported
in Tables 2–6 and include a quality assessment of these trials/studies.
Angiotensin-converting enzyme
inhibitors and angiotensin receptor
blockers
Heart failure with reduced ejection fraction
Two landmark randomized trials in heart failure with reduced ejec-
tion fraction (HFrEF) demonstrated a reduction in mortality with an
ACEI118–120 and one further trial showed a consistent benefit with an
ARB.121 We identified one non-randomized study showing lower
mortality in patients with HFrEF treated with an ACEI.26 Most stud-
ies, however, examined patients treated with either an ACEI or ARB.
Of six such studies, four reported an association between ACEI/ARB
use and lower mortality,26–29 whereas two did not.30 Overall, there-
fore, in HFrEF five non-randomized estimates of treatment ‘effect’
found that use of an ACEI or ARB was associated with lower mortal-
ity and two did not (Table 2).
Heart failure with preserved ejection fraction
One moderately large randomized trial showed no effect of perindo-
pril on mortality, although the estimate of treatment effect was not
robust because of limited power.122 However, two large RCTs
showed no effect of irbesartan123 and candesartan (in Candesartan in
Heart failure: Assessment of Reduction in Mortality and morbidity—
CHARM)124 on mortality. Of eight observational studies examining
ACEI use and outcome in heart failure with preserved ejection frac-
tion (HFpEF), four suggested that use of this treatment was associ-
ated with a lower mortality,31–34 whilst four did not not35–38 (Table
2). We identified one observational study of ARB use in patients with
HFpEF which suggested no mortality benefit.39 A further three non-
randomized studies reported estimates of a treatment ‘effect’ for use
of either an ACEI or ARB in HFpEF. One study found an association
between ACEI/ARB use and better survival29 and two studies did
not.30 Overall, therefore, in HFpEF, five non-randomized studies
found that use of an ACEI or ARB was associated with lower mortal-
ity and seven did not (Table 2).
Mixed/unspecified heart failure phenotype
The CHARM Programme showed a neutral effect of candesartan on
mortality in patients with HFpEF and HFrEF combined.127 Nine non-
randomized studies were identified, which reported 10 estimates of a
Figure 2 Examples of confounding in non-randomized studies.
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.‘treatment-effect’ for use of either an ACEI or ARB in patients with
HFrEF or HFpEF (i.e. both major HF phenotypes). Of these analyses,
eight suggested a benefit40–46 and two reported a neutral effect30
(Table 2).
Beta-blockers
Heart failure with reduced ejection fraction
Several landmark RCTs demonstrated significant mortality benefit with
the use of beta-blockers in HFrEF.128–131 Seventeen non-randomized
studies reported 18 estimates of beta-blocker ‘treatment-effect’.
Sixteen of these suggested beta-blocker use was associated with a
lower mortality28,30,46–58 and two did not30,59 (Table 3).
Heart failure with preserved ejection fraction
The effect of beta-blockers on mortality was examined in one small
randomized trial136 and a pre-specified subgroup analysis of a
randomized trial which included patients with both HFrEF and
HFpEF.132 Overall, we identified 13 non-randomized studies of beta-
blockers in HFpEF, of which nine reported an association between
beta-blocker use and better survival,32,46,50,51,55,60–63 whereas four
did not30,53,64 (Table 3).
Mixed/unspecified heart failure phenotype
One moderately large RCT evaluated the effects of nebivolol in
patients with both HFrEF and HFpEF, demonstrating a neutral effect
on mortality.137 We identified 17 observational studies reporting
19 estimates of the ‘effect’ of treatment, with 17 suggesting bene-
fit,41,44–46,55,65–74 and two reporting no difference in outcome
between those treated with and not treated with a beta-blocker30
(Table 3).
Mineralocorticoid receptor antagonists
Heart failure with reduced ejection fraction
Two pivotal RCTs in HFrEF demonstrated the mortality and hospital-
ization benefits of MRAs.138,139 In contrast, of 12 non-randomized
studies only one concluded MRAs were of benefit,75 with 10 finding
a neutral effect,30,54,76–82 and one suggesting a harmful effect83
(Table 4).
Heart failure with preserved ejection fraction
One large RCT showed no effect of spironolactone on mortality in
patients with HFpEF.141 Two observational studies also found a neu-
tral effect,30,85 but a further non-randomized study reported an asso-
ciation between MRA use and lower mortality84 (Table 4).
Mixed/unspecified heart failure phenotype
Of five studies of patients with a mixed HF phenotype, two suggested
benefit,84,86 and three reported a neutral effect30,46 (Table 4).
Statins
Heart failure with reduced ejection fraction
Two large RCTs showed a neutral effect of rosuvastatin on mortality
in HFrEF (one trial included a small number of patients with
HFpEF).142,144 Sixteen non-randomized studies reported 17 esti-
mates of the ‘effect’ of statin treatment in HFrEF. Of these, 14
reported an association between statin use and better
....................................................................................................
....................................................................................................................................................................................................................
Table 1 Summary of the concordance between the effect of treatment on mortality in randomized controlled trials






ACEI/ARB Benefit 5 2 0
Beta-blocker Benefit 16 2 0
MRA Benefit 1 10 1
Statin Neutral 14 3 0
Digoxin Neutral 1 4 5
HFpEF
ACEI/ARB Neutral 5 7 0
Beta-blocker Neutral 9 4 0
MRA Neutral 1 2 0
Statin — — — —
Digoxin Neutral 1 3 0
Mixed/unspecified HF phenotype
ACEI/ARB Neutral 8 2 0
Beta-blocker Neutral 17 2 0
MRA — 2 3 0
Statin Neutral 11 1 0
Digoxin Neutral 2 7 7
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure
with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist.
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outcome,28,59,87–97 whereas only three found no association30,59,98
(Table 5).
Heart failure with preserved ejection fraction
The use of statins has not been evaluated in a randomized trial in
patients with HFpEF, therefore, no relevant non-randomized studies
were identified.
Mixed/unspecified heart failure phenotype
One large statin trial included patients with both HFrEF and HFpEF
and showed no effect of treatment on mortality.144 Eleven observa-
tional studies reported 12 estimates of the ‘effect’ of a statin in
patients with a mixture of HFrEF and HFpEF phenotypes, or where
EF was not specified. Of these, 11 reported an association between
statin use and better outcome,45,68,88,98–104 with only one describing
no relationship between treatment and mortality30 (Table 5).
Digoxin
Heart failure with reduced ejection fraction
A single RCT, the Digitalis Investigators Group (DIG) trial, showed
that, in sinus rhythm, digoxin had a neutral effect on death but
reduced the risk of HF hospitalization.145 Nine non-randomized stud-
ies reported 10 estimates of the ‘effect’ of digoxin treatment in
HFrEF, with five concluding digoxin was harmful,107–110 four report-
ing a neutral effect,30,55,106 and one suggesting digoxin was benefi-
cial105 (Table 6).
Heart failure with preserved ejection fraction
A single randomized trial of modest size, the DIG ancillary trial in
HFpEF (n= 988), showed no effect of digoxin on mortality in patients
with HFpEF in sinus rhythm, although the estimate of the effect of
treatment was not robust because of limited power.146 Four obser-
vational studies were identified, one suggesting that non-randomized
digoxin treatment was beneficial,105 and three showing a neutral as-
sociation between treatment and mortality30,55 (Table 6).
Mixed/unspecified heart failure phenotype
The combined main and ancillary DIG trials showed a neutral effect
of digoxin on mortality.147 Fourteen observational studies reported
effect estimates for digoxin in patients with HFrEF and HFpEF in com-
bination, or where EF was not specified. These studies reported 16
estimates of ‘treatment-effect’. Seven found an association between
the use of digoxin and a higher mortality,41,65,113–117 seven were neu-
tral,30,42,55,112,113 and two suggested better outcomes associated with
digoxin use105,111 (Table 6).
Discussion
There is a particularly strong evidence base for the treatment of HF,
making it an appropriate condition in which to compare treatment
effects established in RCTs with those estimated in non-randomized
and observational studies.
Looking first at patients with HFrEF, six observational studies
(reporting seven ‘effect’ estimates) fulfilled our inclusion criteria, and
examined the association between treatment with an ACEI/ARB and
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receiving treatment of this type,26–29 whereas two did not,30 i.e. there
was relatively good concordance between these non-randomized
studies and the pivotal RCTs. However, the same concordance was
not found in studies in HFpEF (see below).
The non-randomized analyses of beta-blockers in HFrEF also
showed good agreement with the RCTs, with 16 of 18 analyses con-
cordant.28,30,46–59 However, this was not the case in observational
studies of patients with a mixed HF phenotype, where the Study of
the Effects of Nebivolol Intervention on Outcomes and
Rehospitalisation in Seniors with Heart Failure (SENIORS) trial had
shown a neutral effect on mortality.137 Of the 19 non-randomized
analyses, 17 showed a lower mortality among patients of this type
treated with a beta-blocker.30,41,44–46,55,65–74
However, the picture was quite different for MRAs, which reduce
mortality in HFrEF. Of 12 observational studies, one reported lower
mortality in patients treated with a MRA,75 10 did not find a better or
worse outcome (i.e. were neutral),30,54,76–82 and one found a higher
mortality (worse outcome) in the MRA treated patients.83 It is worth
exploring this discordance in more detail. By far the largest study
included 18 852 patients from Sweden and is worth examining in de-
tail.79 The authors of this study used matching of spironolactone
treated (n= 6551) and untreated (n= 12 301) patients. The authors
also attempted to adjust for residual confounding in several different
ways. Despite these statistical approaches, the multivariate HR for
all-cause mortality with spironolactone vs. no spironolactone was
1.05 [95% confidence interval (CI) 1.00–1.11; P= 0.054] in the model
adjusted for propensity score and 1.10 (95% CI 1.02–1.19; P= 0.020)
in a 1:1 matched model. These findings stand in stark contrast to two
separate trials of MRAs in HFrEF. The authors of the above observa-
tional study argued that the severity of HF symptoms and concomi-
tant use of beta-blockers might explain the difference between their
findings and the Randomized Aldactone Evaluation Study (RALES)
trial, which used spironolactone in severely symptomatic patients,
few of which were treated with a beta-blocker.139 However, patients
with mild symptoms, the large majority of which were treated with a
beta-blocker, were enrolled in the Eplerenone in Mild Patients
Hospitalization And Survival Heart Failure (EMPHASIS-HF) trial,
which demonstrated a clear mortality benefit of the MRA eplere-
none.138 As an alternative explanation for their discrepant findings,
the authors postulated that trial inclusion/exclusion criteria select
patients more likely to benefit and less likely to experience harm
pointing out, for example, the younger average age of patients in
RALES (65 years) compared with the Swedish registry (71 years);
however, the average age in EMPHASIS-HF was 69 years. In any case
(and counterintuitively), the authors own analysis showed a signifi-
cant treatment-by-age interaction whereby older (rather than
younger) patients did better with MRA treatment.79 Several other of
the authors’ subgroup analyses (e.g. significantly better outcome with
an MRA in patients without diabetes compared to with diabetes) are
directly contradicted by independent but consistent subgroup analy-
ses from RALES and EMPHASIS-HF. The authors of the Swedish
study also speculated that patients in the ‘real-world’ treated with a
MRA maybe at greater risk of harm because of less careful monitor-
ing of renal function and potassium.
Another notable example of a discrepancy between observational
data and randomized trials does address issues of safety and general-
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estimates suggested that statins have a mortality benefit in
HFrEF,28,30,59,87–98 yet two large independent RCTs showed no effect
of this type of treatment on death.142,144 In patients with the mixed/
unspecified HF phenotype, a further 11 of 12 analyses reported an as-
sociation of statin use with mortality benefit.30,45,68,88,98–104 Again, it
is instructive to examine one of the observational studies in detail.
Go et al.104 used a Kaiser Permanente dataset with almost 25 000
patients to conduct careful propensity score-adjusted analyses of
outcome related to statin treatment; the authors also used time-
varying covariate adjustment for statin initiation during follow-up.
The adjusted HR for all-cause mortality in patients treated with a sta-
tin (compared with those who were not) was 0.66 (95% CI 0.61–
0.71) in individuals with CHD and 0.60 (95% CI 0.54–0.67) in those
without CHD. Apart from the improbably large ‘reduction’ in mortal-
ity (34–40%), the similar ‘effect’ in patients with and without CHD
seems unlikely given everything we know about the actions of statins.
Moreover, the prior arguments made about generalisability and safety
would need to be inverted here as the observational datasets
included broad populations of patients with HF, presumably, receiv-
ing less intense monitoring than in the clinical trials.
Even in HFpEF, there are clearly discrepant findings between a
large observational dataset and two randomized trials with an
ARB123,124 and one trial with an ACEI.122 Once again, the most obvi-
ous example involves the Swedish HF registry.29 As previously, the
authors of this study used an age- and propensity score-matched co-
hort. The adjusted HR for all-cause mortality in patients treated with
an ACEI or ARB, compared with those not treated with one of these
agents, was 0.90 (95% CI 0.85–0.96; P= 0.001). The authors also
described a ‘dose–response’ relationship whereby the HR for high-
dose treatment compared with no treatment was 0.85 (95% CI 0.78–
0.83) and compared with low-dose treatment was 0.94 (95% CI
0.87–1.02). For this study, the authors used the issue of generalisabil-
ity to explain why they saw benefit compared with the prior trials, in
contradistinction to the case for MRAs where the opposite argument
was made. Specifically, in this case, with ACEIs and ARBs, they argued
that the broader, older and higher-risk population in the registry
responded favourably to treatment compared with the more
selected participants enrolled in the trials.
Much has been written recently in relation to the safety of digoxin
in atrial fibrillation. Indeed, in a very illustrative example of the unreli-
ability of observational data, Bavendiek et al.148 highlighted how in
three separate and independent post hoc analyses of the same dataset,
digoxin treatment was variably associated with increased all-cause
mortality, was not associated with increased mortality and, in the
third analysis, was associated with decreased in mortality in patients
with an EF less than 30%. In HF, there is the same type of discrepancy
between observational data and the single large RCT in HFrEF, an an-
cillary trial in HFpEF, and the combined analysis of the effect of di-
goxin in both HF phenotypes.145–147 In each of these analyses,
digoxin had a neutral effect on all-cause mortality. A total of 30 ob-
servational analyses variously show better, worse, and neutral out-
comes.30,41,42,55,65,105–117
Why the non-randomized analyses of outcomes related to use of
ACEI/ARB and beta-blockers in HFrEF were generally (but not abso-
lutely) concordant with the RCTs, in contrast to the other treat-
ments examined, is an interesting question. There may be less
confounding by indication, i.e. ACEIs/ARBs and beta-blockers are
recommended in essentially all patients with HFrEF, whereas digoxin
and, at least until recently, MRAs were reserved for patients with
more advanced HF. There may also have been particularly strong
publication bias making it difficult to report studies suggesting that
use of ACEIs/ARBs or beta-blockers is not associated with better
outcomes (or even associated with worse outcomes). Of course,
with both treatments there is also a strong selection bias whereby
the sickest patients are least likely to be prescribed (and to tolerate)
these therapies. The opposite consideration may apply to the non-
randomized studies showing an association between treatments such
as statins and lower mortality, with the possibility of other biases
such as the ‘healthy-user effect’ not fully adjusted for.
Although our analyses show that the findings of non-randomized
studies of the association between treatment use and outcomes are
frequently inconsistent, they do not mean observational studies/
registries are of no value. Registry-based analyses may be all that is
available where randomized trials are not possible, such as in rare dis-
eases or for rare outcomes. The latter forms the basis of pharmaco-
epidemiological surveillance for rare adverse effects of drugs not
identified in clinical trials. Non-randomized analyses may provide in-
formation on under-studied groups or subgroups excluded from clin-
ical trials. However, the results of such analyses must be interpreted
with caution, especially if the results of different analyses of this type
conflict. Registries serve an important function in describing the use
(or under-use) of evidence-based therapies in the ‘real-world’, often
leading to initiatives to improve prescribing. Perhaps the greatest
value of registries is the potential they offer to conduct more ‘real-
world’ randomized trials, i.e. to randomize patients in a registry to
treatment and follow their outcomes within the registry. This ap-
proach has been pioneered in a study of thrombus aspiration in ST-
segment elevation myocardial infarction using the Swedish Coronary
Angiography and Angioplasty Registry149 and a similar approach is
now being used to conduct the Spironolactone Initiation Registry
Randomized Interventional Trial in Heart Failure with Preserved
Ejection Fraction (SPIRRIT-HFpEF)150 in the Swedish HF Registry
[NCT02901184].
Our study has a number of strengths and limitations. The strengths
include the robust evidence base in HF, with often more than one
randomized trial supporting the use or avoidance of specific thera-
pies. There is a specific limitation in relation to the effect of MRAs in
HFpEF. In the single, prospective, RCT, ineligible patients were
included, and study drug was not administered, at certain investigative
sites.141 As a result, the integrity of the trial has been questioned, as
has the overall treatment effect observed.151 Examination of the ef-
fect of therapy in regions where the trial is thought to have been con-
ducted as intended suggested possible benefit of spironolactone,
compared with placebo.140 Consequently, the effect of spironolac-
tone in this RCT and in the one observational analysis which sug-
gested no benefit from MRA therapy may not be in agreement.
Conclusion
This comprehensive comparison of the robust evidence base in HF
with an increasing number of non-randomized data shows that it is
not possible to make reliable therapeutic inferences from observa-
tional associations. While trials undoubtedly leave gaps in evidence
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and enrol selected participants, they clearly remain the best guide to
the treatment of patients.
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Supplementary material is available at European Heart Journal online.
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